Navigation Links
New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity
Date:7/22/2014

he first aesthetic technology that applies the “science of heat” using temperature as a clinical endpoint enabling plastic surgeons and aesthetic physicians to precisely heat soft tissue and nerves to achieve desired aesthetic outcomes. ThermiRF is also the first aesthetic device to deploy simultaneous dual monitoring of tissue temperature (internal and external) using advanced infrared imaging for precision treatments and unparalleled safety.

About ThermiAesthetics
ThermiAesthetics is a global manufacturer of state of the art aesthetic technology. The company’s mission is to provide solutions for cosmetic physicians who are caring for aesthetic patients who seek to reverse the effects of aging. ThermiAesthetics solutions include ThermiTightTM for skin laxity, ThermiRaseTM for unwanted frown lines, ThermiSmoothTM for wrinkles and skin irregularities, among other applications.

For more information, please visit http://www.thermi.com or http://www.thermitight.com.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12010955.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Obese appendectomy patients have fewer complications with minimally invasive operations
2. Minimally invasive surgery works well for abdominal aortic aneurysms, Mayo finds
3. Minimally invasive lymph node dissection in breast cancer has advantages over conventional surgery
4. New technique for minimally invasive robotic kidney cancer surgery
5. Fox Valley Orthopedics Surgeon Dr. Craig Popp Says New Minimally Invasive Herniated Disc Surgery Less Painful
6. Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse (POP) Now Available from the Specialists at Women’s Excellence in Bladder Control in Clarkston, MI
7. Study shows long-term efficacy of minimally invasive therapy for patients with Barretts esophagus
8. Minimally Invasive Surgery for Treatment of Colorectal Cancer Yields Optimal Outcomes for Patients
9. Kidney stone surgery: More women, more complications with minimally invasive procedure
10. Top Surgeons to Convene for SAGES 2013 Conference to Feature Breakthroughs in Gastrointestinal, Robotic and Minimally Invasive Surgery
11. New minimally invasive, MRI-guided laser treatment for brain tumor found to be promising in study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the first cannabis ... at the Caribe Royal All Suites Hotel and Convention Center in Orlando, Florida, October ... medical cannabis expo in the country and this year’s expo will be the first ...
(Date:7/30/2015)... Ferry, New York (PRWEB) , ... July 31, 2015 , ... ... Barack Obama’s call to action by asking community members to contribute to the College’s ... on, “Helping more of our young people stay on track. Providing the support they ...
(Date:7/30/2015)... ... 30, 2015 , ... OSF Healthcare System has been recognized as ... Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive year for ... The Sisters of the Third Order of St. Francis . , Health data security ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca ... on the go. With no water needed, the refreshing berry-flavored tablets are the ... to get the natural ingredients that may help with body detoxification, protection and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and ... cutting-edge health care technology vendors, will take place May 14-17, 2016 in Minneapolis, ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... gap is alive and well in heart disease, a new international ... to treatment in both heart attack and severe chest pain. ... twice as likely as men to have normal or mild results ... blockage taking up more than 50 percent of any one blood ...
... ... Flows Increase, BIRMINGHAM, Ala., May 6 HealthSouth,Corporation (NYSE: ... first quarter ended March 31, 2008. Compared to the,first quarter of ... net income increased by $76.4 million., "The results of the ...
... and,Mississippi still working to recover from the Hurricane Katrina ... Department of,Health and Human Services (HHS)., "HHS continues ... health care,problems created by Hurricane Katrina," Secretary Mike Leavitt ... make sure the citizens of these,states have continued access ...
... Today at 5:30 p.m. EDT, FRAZER, Pa., ... that a Joint Advisory Committee to the U.S. ... approval of an expanded,label for FENTORA(R) (fentanyl buccal ... opioid-tolerant patients with chronic pain conditions.,The panel expressed ...
... have shown for the first time that thrombopoietin (TPO), ... to increase platelet count in cancer patients during chemotherapy, ... heart attack. , The study, led by ... the division of cardiothoracic surgery, was published in the ...
... now register to attend TCT2008 (Transcatheter Cardiovascular Therapeutics), ... Foundation. TCT gathers leading medical researchers and clinicians ... developments in the field of interventional cardiology and ... state-of-the-art techniques and training to interventional cardiologists around ...
Cached Medicine News:Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 2Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 2Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 4Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 5Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 6Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 7Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 8Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 9Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 10Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 11Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 12Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 13Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 14Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 15Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 16Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 17Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 18Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 19Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 20Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 21Health News:Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 3Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 4Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 5Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 6Health News:Naturally-occuring protein may be effective in limiting heart attack injury and restoring function 2Health News:Media registration now open for TCT2008 2
(Date:7/31/2015)...  Semler Scientific, Inc. (Nasdaq: SMLR ), a ... insurers and physician groups, today reported financial results for ... "In the second quarter of 2015, Semler reported ... 54%, quarter over quarter revenue growth of 8%, and ... FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., chief ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
Incontinence Pessaries...
Medicine Products: